Results 111 to 120 of about 1,005 (158)

PEGylated chitosan xerogels for localized periodontal therapy: design, characterization, and drug release. [PDF]

Sci Rep
Zafar F, Sheraz MA, Ali SA, Riaz M, Ahmed S, Kazi SH, Tariq S, Anwar Z.   +7 more
europepmc   +1 more source

Enhanced colon-targeted drug delivery through development of 5-fluorouracil-loaded cross-linked mastic gum nanoparticles. [PDF]

Sci Rep
Hani U, Mahammed N, Reshma T, Talath S, Wali AF, Aljasser A, Al Fatease A, Alamri AH, Khan S.   +8 more
europepmc   +1 more source

Review on transdermal patches: optimization in drug administration. [PDF]

Colomb Med (Cali)
Sarmiento Giraldo JJ, Gonzalez Ospina J, Moncada F, Calad AM.   +3 more
europepmc   +1 more source

Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report. [PDF]

Mol Pharm
Tannergren C, Arora S, Babiskin A, Borges L, Chatterjee P, Cheng YH, Dallmann A, Govada A, Heimbach T, Hingle M, Kollipara S, Kotzagiorgis E, Lindahl A, Mackie C, Malamatari M, Mitra A, Moody R, Pepin X, Polli J, Raines K, Rullo G, Sanghavi M, Savkur R, Singh R, Sjögren E, Suarez-Sharp S, Thomas S, Veerasingham S, Wei K, Wu F, Xu Y, Yoon M, Rege B.   +32 more
europepmc   +1 more source

Bridging the Gap: The Role of Advanced Formulation Strategies in the Clinical Translation of Nanoparticle-Based Drug Delivery Systems. [PDF]

Int J Nanomedicine
Herdiana Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nanomedicine at the crossroads – A quick guide for IVIVC

Advanced Drug Delivery Reviews, 2021
For many years, nanomedicine is pushing the boundaries of drug delivery. When applying these novel therapeutics, safety considerations are not only a key concern when entering clinical trials but also an important decision point in product development.
Marc-Phillip Mast, Harshvardhan Modh, Carole Champanhac, Jiong-Wei Wang, Gerrit Storm, Johannes Krämer, Volker Mailänder, Giorgia Pastorin, Matthias G. Wacker   +8 more
openaire   +3 more sources

Use of the BioDis to generate a physiologically relevant IVIVC

Journal of Controlled Release, 2008
In the last decades there has been continual interest in site-specific delivery to the colon. Recently, new types of site-specific delivery formulations have been developed for the treatment of ulcerative colitis and other colon related diseases. The aim of the present study was to establish a physiologically relevant IVIVC for two prototypes using a ...
Sandra Klein, Jennifer B Dressman
exaly   +3 more sources

IVIVC of controlled release formulations: Physiological–dynamical reasons for their failure

Journal of Controlled Release, 2008
Aristides Dokoumetzidis, Panos Macheras   +1 more
exaly   +5 more sources

Development strategies for IVIVC in an industrial environment

Biopharmaceutics and Drug Disposition, 2012
ABSTRACTProduct development is typically challenging. There is a strong desire to understand critical performance factors early in order to optimize formulations for Phase III trials or marketing approval. However, over 90% of drugs entering development in humans do not make it to the market.
Jack A Cook
exaly   +3 more sources

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions [PDF]

AAPS Journal, 2015
In vitro-in vivo correlations (IVIVCs) play an important role in formulation development and drug approval. At the heart of IVIVC is deconvolution, the method of deriving an in vivo "dissolution profile" for comparison with in vitro dissolution data.
Adam S Darwich, Aleksandra Galetin, Amin Rostami-Hodjegan   +2 more
exaly   +4 more sources